|
|
||||||||
,
Departments of
*
Internal Medicine and
Medical Microbiology and Immunology, University of Missouri, and
Veterans Administration Research Service, Columbia, MO 65212
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
B cells are important for the development of several spontaneous autoimmune diseases including diabetes in NOD mice (6, 7, 8), SLE in MRL/Mp-lpr/lpr mice (9, 10) and arthritis in K/BxN mice (11). In addition, some experimentally induced autoimmune diseases, including experimental autoimmune thyroiditis, collagen-induced arthritis and experimental allergic encephalomyelitis (EAE) either do not develop or develop suboptimally in B cell-deficient mice (Refs. 12, 13, 14, 15, 16 and H.B.-M., unpublished results). The purpose of these studies was to determine whether B cells and/or autoantibodies produced by B cells were required for the development of SAT in NOD.H-2h4 mice. The results indicate that development of SAT is severely compromised in B cell-deficient mice. B cells are apparently required some time during the first 46 wk after birth, and their function cannot be replaced by anti-MTg autoantibodies.
| Materials and Methods |
|---|
|
|
|---|
NOD.H-2h4 mice, derived by crossing NOD mice with B10.A(4R) mice, with repetitive backcrosses to NOD using progeny expressing the MHC haplotype of B10.A(4R), were provided by Dr. Linda Wicker (Merck, Rahway, NJ), and subsequently bred and maintained under specific pathogen-free conditions in the animal facilities at the University of Missouri (3). B lymphocyte-deficient NOD.Igµnull mice (6) were provided by Dr. David Serreze (The Jackson Laboratory, Bar Harbor, ME). NOD.Igµnull males were crossed with NOD.H-2h4 females and the resulting F1 mice were bred to produce F2 mice. The F2 progeny were selected for homozygosity at H-2Kk and lack of expression of H-2Kd and for expression of the B cell markers B220 and IgM (Igµ+) or lack of expression of B220 and IgM (Igµnull) by flow cytometric analysis of PBLs. Homozygous Igµ+ mice were then selected by PCR analysis of tail DNA using published PCR primer sequences (6). The resultant homozygous Igµ+ or Igµnull H-2K mice, hereafter designated NOD.Kµ+ and NOD.Kµnull, were bred and maintained under specific pathogen-free conditions, and the offspring were used for the studies reported here. Mice were age- and sex-matched for each individual experiment; both male and female mice were used for these experiments. All mice received 0.05% NaI in their drinking water beginning at 78 wk of age (3), or in the bone marrow reconstitution experiments, at 12 wk of age.
B cell depletion with anti-IgM
For some experiments, B cells were depleted from newborn mice using rabbit anti-mouse IgM (Southern Biotechnology Associates, Birmingham, AL or Jackson ImmunoResearch, West Grove, PA) as described previously (17). Mice received anti-IgM s.c. within the first 24 h after birth and three times weekly thereafter (50 µg/injection), either throughout the experiment (16 wk) or for 14 wk after birth as specified in the Tables. When mice were 3 wk old, anti-IgM was administered i.p. instead of s.c. This regimen of anti-IgM treatment, if initiated within 24 h of birth, results in essentially complete depletion of peripheral B cells (IgM+ and B220+ cells) as determined by flow cytometry, and has no apparent effects on T cells. This reagent is not effective for depletion of B cells when treatment is begun later (Ref. 17 and our unpublished observations). In the experiments shown here, control mice were injected with saline. Previous studies (Ref. 17 and our unpublished observations) have shown that mice given a control rabbit Ig have normal numbers of B lymphocytes, and development of SAT and immune responses to exogenous Ags are indistinguishable from those of saline-injected mice.
Irradiation, bone marrow, and B cell reconstitution
Male NOD.Kµ+ or
µnull mice were lethally irradiated (1000 rad)
at 5 wk of age and reconstituted with 9 x
106 T cell-depleted syngeneic bone marrow cells
from syngeneic NOD.Kµ+ or
µnull donors. Some mice also received 2 x
107 B cells (CD4- and CD8-depleted splenocytes)
from adult (3- to 4-mo-old) NOD.Kµ+ mice.
Analysis of PBLs 9 days after irradiation and bone marrow
reconstitution indicated that the irradiation adequately depleted
mature CD4+ T cells and B cells in the recipient
mice (irradiated bone-marrow reconstituted mice had <2%
CD4+ T cells and <3%
B220+ cells in peripheral blood, similar to
background values using isotype control Abs). Six weeks after
irradiation and bone marrow reconstitution, CD4+
T cells and B220+ cells substantially increased
in the peripheral blood, but were still reduced compared with
unirradiated controls (see Table V
). Mice that received
NOD.Kµnull bone marrow plus B cells had
variable, but clearly detectable, levels of circulating
B220+ cells at this time;
B220+ cells were only slightly lower than the
B220+ cells in mice reconstituted with
µ+ bone marrow (Table V
). One week later (7 wk
after irradiation and bone marrow reconstitution), all mice were given
NaI water, and were assessed for SAT 12 wk later. The time the mice
were on NaI water was increased to 12 wk because preliminary
experiments indicated that development of SAT was suboptimal at 8 wk in
NOD.Kµ+ recipients of
µ+ bone marrow, presumably due to
immunosuppression from the irradiation.
|
Eight to 9 wk (or 12 wk in Table V
) after mice began receiving
NaI in their water, thyroids were collected, fixed in formalin,
sectioned, and stained with hematoxylin and eosin as previously
described (3, 18). As shown previously (3),
thyroid lesions reach maximal severity 79 wk after NOD.H-2h4 mice are
given NaI in their drinking water beginning at 2 mo of age; the lesions
are chronic and remain relatively unchanged in severity for at least
the next 20 wk (our unpublished observations). The
NOD.Kµ+ mice described above developed SAT with
similar severity and kinetics to the NOD.H-2h4 mice. Thyroids were
scored for the extent of follicle destruction (SAT severity) using a
scale of 1+ to 4+ as
previously described (3). Briefly,
1+ thyroiditis is defined as an infiltrate of at
least 125 cells in one or several foci, 2+
represents 1020 foci of cellular infiltration, each the size of
several follicles and involving up to 1/4 of the gland,
3+ indicates that 1/4 to 1/2 of the gland is
destroyed by infiltrating inflammatory cells, and
4+ indicates that greater than 1/2 of the gland
is destroyed. Qualitatively, the thyroid inflammatory cell infiltrate
was typical of that seen in conventional lymphocytic experimental
autoimmune thyroiditis, consisting primarily of lymphocytes and other
mononuclear cells with occasional polymorphonuclear and plasma cells
(3, 18). Most thyroids also had some proliferation and
enlargement of thyroid follicular cells. Follicular cell enlargement
was evident even in many thyroids with insufficient inflammatory cell
infiltration to receive a severity score of 1+,
and was probably a consequence of the increased dietary iodine. All
slides were coded before being scored by two individuals, one of whom
had no knowledge of the experimental protocol.
Autoantibody determination
MTg-specific autoantibodies were assessed by ELISA using serum from individual mice as previously described (3, 19). Alkaline phosphatase-conjugated secondary Abs specific for total mouse IgG or for mouse IgG1 and IgG2B were used at previously determined optimal dilutions (1:6000 or 1:8000), which gave an OD <0.05 with 1:50 diluted normal mouse serum on MTg-coated plates or with a 1:50 dilution of each test serum on plates coated with an irrelevant protein (OVA). Plates coated either with highly purified MTg or with less purified MTg preparations always gave identical results in this assay, suggesting that the IgG1 and IgG2b autoantibodies are directed against thyroglobulin, and not against another thyroid protein (3).
Flow cytometry
Spleen cells or PBL from experimental mice were analyzed for cell surface expression of B220, IgM, CD4, and CD8 by flow cytometry (FACSvantage; Becton Dickinson, San Jose, CA) as previously described (17). FITC-conjugated Abs specific for mouse B220, CD4, and CD8 were obtained from Caltag (South San Francisco, CA) and FITC-conjugated anti-mouse IgM was obtained from Southern Biotechnology Associates. MHC class I expression by PBL to identify NOD.K mice that were homozygous for H-2Kk and that lacked the H-2Kd allele expressed by NOD mice was determined using the mAbs 16-1-11N (anti-Kk; HB-16; American Type Culture Collection, Manassas, VA) and SF-1.1.1 (anti-Kd; HB-159; American Type Culture Collection) followed by a FITC-conjugated goat anti-mouse IgG (Boehringer Mannheim, Indianapolis, IN).
Statistical analysis
A two-tailed Students t test was used to determine the significance of differences in SAT severity between different groups. The p values are given in the footnotes in the tables.
| Results |
|---|
|
|
|---|
To determine whether B cells were required for development of SAT,
NOD.H-2h4 mice were given anti-IgM beginning at birth and
continuing through the entire 16 wk of the experiment as described in
Materials and Methods. As shown in Table I
, lines 1 and 2, 6 of 11 anti-IgM
treated mice did not develop SAT, and the other 5 mice had mild
(1) thyroiditis. Most of the
thyroids of B cell-deficient mice with 1+
severity scores had only one to two foci of inflammatory cells, the
minimal criteria for receiving a 1+ score (see
Materials and Methods). In contrast, all 10 age-matched
saline-injected control mice developed SAT, with 9 of 10 mice having a
severity score of 2+-4+.
All control mice had anti-MTg IgG1 and IgG2b autoantibodies, while
anti-MTg autoantibodies were not significantly above background in
sera of anti-IgM treated mice. Similar results were observed for
mice genetically lacking B cells due to deletion of the Igµ gene
(Table I
, lines 3 and 4). Both anti-IgM treated NOD.H-2h4 mice and
NOD.Kµnull mice had essentially undetectable
B220+ and IgM+ cells both
in peripheral blood (data not shown) and spleen (Fig. 1
and footnote, Table I
), with increased
percentages of CD4+ (Fig. 1
) and
CD8+ T cells (data not shown) compared with
controls. These results indicate that B cells are required for optimal
development of SAT in NOD.H-2h4 and NOD.K mice, although mild thyroid
lesions do develop in some mice in the absence of B cells and
autoantibodies.
|
|
To begin to define the function of B cells in SAT, it was of
interest to determine whether B cell reconstitution at 68 wk of age
(before mice begin NaI water, and several weeks before thyroid lesions
develop in B cell-intact mice; Ref. 3) would enable
NOD.H-2h4 mice to develop SAT. Adult NOD.Kµnull
mice could not be reconstituted with B cells from
NOD.Kµ+ mice (Table III
, lines 6 and 7, and
data not shown), presumably because the transferred B cells were
rejected by CD8+ T cells (20) or
inhibited by CD4+ T cells (21) of
the B cell-deficient mice. Therefore, the approach we used to
reconstitute B cell-depleted mice with B cells was to stop the
anti-IgM treatment at various times (13 wk) after birth and allow
peripheral B cells (B220 and IgM+ cells) to
gradually repopulate the mice. Although there was some variation in the
rate of B cell reconstitution with different lots of anti-IgM, B
cell percentages in peripheral blood usually returned to near normal
levels (as determined by flow cytometry) 23 wk after stopping the
anti-IgM treatment. In the first experiment (Table II
, lines 13), mice were treated with
anti-IgM for the first 3 wk after birth. When mice were 6 wk old (2
wk before starting NaI water and 45 wk before detectable thyroid
lesions would develop in B cell-intact mice; Ref. 3),
percentages of B220+ (Table II
, line 3),
IgM+, and CD4+ cells (not
shown) in peripheral blood were similar to those of controls (line 1).
However, mice treated with anti-IgM for only 3 wk after birth (line
3) had an incidence and severity of SAT comparable to mice in which B
cell depletion was maintained throughout the experiment (line 2). In a
second experiment, mice that received anti-IgM for only 1 wk (Table II
, line 5) had normal percentages of peripheral B cells when tested at
6 wk of age, whereas mice given anti-IgM for 3 wk still had
slightly lower percentages of peripheral B220+
cells at 6 wk (line 6). Mice given anti-IgM for only 1 wk were as
resistant to SAT as mice treated with anti-IgM for 3 wk (line 6)
or, in other experiments, through the entire 16 wk of the experiment.
These results suggest that B cells are required sometime during the
first 46 wk after birth for optimal development of SAT in adults, and
the presence of normal numbers of B cells at 6 wk of age is not
sufficient to promote development of SAT. Another possible
interpretation of these results is that SAT development could simply be
delayed in mice given anti-IgM for only 13 wk after birth. To
address this possibility, half of the controls and half of the mice
treated with anti-IgM for 3 wk in the second experiment in Table II
were maintained on NaI water an additional 8 wk. As shown in Table II
,
lines 7 and 8, SAT severity scores in both groups assessed at 24 wk
were not significantly different from those of each respective group at
16 wk (lines 4 and 6). This suggests the early absence of B cells does
not simply delay development of SAT.
|
|
Mice in which B cell depletion was maintained through 16 wk did
not produce detectable anti-MTg autoantibodies (Table I
and Table II
, line 2). However, when anti-IgM treatment was stopped after
13 wk, most mice produced detectable anti-MTg autoantibodies,
even though many of them did not develop thyroid lesions. Although the
results shown in the Tables represent the mean ELISA results of the
group, the mice having SAT severity scores of 1+
did not contribute all the autoantibody to the group mean. In all these
experiments, anti-IgM treated mice with 1+
SAT severity scores had autoantibody responses that were
indistinguishable from those of mice in the same group that had scores
of 0 (data not shown). Anti-MTg autoantibodies were always much lower
in the 13 wk B cell-depleted mice compared with controls, possibly
because their B cells did not develop for several weeks after birth
and, therefore, became activated later. When such mice were maintained
on NaI water through 24 wk (Table II
, line 8), their anti-MTg IgG2b
responses were comparable to those of controls (Table II
, line 7), and
IgG1 responses were higher than at 16 wk. Because these mice developed
minimal or no SAT, the decreased autoantibody levels probably do not
explain their relative resistance to SAT. In other experiments, mice
depleted of B cells for 4 wk after birth were given serum containing
anti-MTg autoantibodies from NOD.H-2h4 mice with SAT. Ab injections
were begun at 11 wk (3 wk after the mice began NaI water, when
autoantibodies first become detectable in controls; Ref.
3) and were continued weekly through 16 wk (Table III
, lines 13). Although IgG1
autoantibodies in mice receiving passive anti-MTg were lower than
in controls, anti-MTg IgG2b levels were comparable to those of
controls. However, mice given passive anti-MTg did not develop SAT,
suggesting that a lack of circulating anti-MTg autoantibody may not
be the critical factor responsible for the relative resistance of B
cell-depleted mice to SAT. In another experiment, B cell-deficient
NOD.Kµnull mice were given B cells from
NOD.Kµ+ mice at 8 and 10 wk of age, and weekly
injections of serum from MTg-immunized CBA/J mice containing high
amounts of anti-MTg (Table III
, lines 47). As noted above, B cell
reconstitution in adult NOD.Kµnull mice was not
effective (20, 21), and the mice did not develop SAT (line
6). Mice receiving passive anti-MTg autoantibodies had higher
levels of anti-MTg than controls, but they did not develop SAT
(line 7). These results suggest the sole requirement for B cells is
probably not to produce anti-MTg autoantibodies, although we cannot
exclude the possibility that the transferred Ab differs in some
important way, or does not gain access to the thyroid in the same way,
as anti-MTg autoantibodies that develop spontaneously. In the
experiment shown in Table IV
, adult
NOD.Kµnull mice could be stably repopulated
with B cells from NOD.Kµ+ mice when they were
irradiated (500 rad) before B cell transfer (line 3 vs line 4).
Although many of these mice had fewer splenic B cells than control
µ+ mice, the B cells were functional because
the B cell-repopulated mice spontaneously produced as much anti-MTg
IgG1 and IgG2b autoantibody as control µ+ mice
(Table IV
, line 4 vs lines 1 and 2). However, even though anti-MTg
autoantibodies developed spontaneously and reached levels comparable to
those of NOD.Kµ+ mice, B cell-repopulated
irradiated NOD.Kµnull mice did not develop SAT.
In contrast, 9 of 10 irradiated and nonirradiated
NOD.Kµ+ mice developed SAT (i.e., 500 rad
irradiation did not inhibit development of SAT in
µ+ mice). As shown above, unirradiated
NOD.Kµnull mice could not be reconstituted with
B cells, and they did not develop SAT or produce anti-MTg
autoantibodies (Table IV
, line 3). These results indicate that mice
given B cells as adults can spontaneously produce normal levels of
circulating anti-MTg autoantibodies, but this does not enable them
to develop SAT.
|
The results presented above indicate that B cells are required
during the first 46 wk of life for optimal development of SAT, and
this is probably not due solely to a requirement for circulating
anti-MTg autoantibodies. If the inability of B cell-deficient mice
to develop SAT is due to a lack of B cells during a critical time in
the first 46 wk after birth, NOD.Kµnull mice
should develop SAT if they are given B cells within 12 wk after
birth. However, we were unable to achieve stable reconstitution of
peripheral B cells when NOD.Kµnull mice were
given adult B cells at 1 or 2 wk of age (not shown). This is presumably
due to the inhibitory effects of NOD.Kµnull T
cells on transferred B cells mentioned above (20, 21).
However, Ighµnull mice can be stably
reconstituted with B cells when their T cells mature from immature bone
marrow precursors in the presence of B cells (20). This
provided an alternative means to determine whether B cell-deficient
NOD.Kµnull mice could develop SAT if B cells
were available when their T cells were maturing. To address this
question, lethally irradiated mice were repopulated with bone marrow
from either NOD.Kµ+ or
µnull mice as a source of precursor T cells.
Some mice also received B cells from adult
NOD.Kµ+ mice (Table V
). Analysis of peripheral blood cells 9
days after irradiation and bone marrow reconstitution indicated that
mature T and B lymphocytes resident in recipients were adequately
destroyed by the irradiation (see Materials and Methods).
Six weeks after bone marrow reconstitution, peripheral blood
CD4+ T cells were present at >50% of control
values in most mice. Mice that received µ+ bone
marrow (lines 2 and 5) or µnull bone marrow
plus B cells from µ+ mice (lines 4 and 6) had
variable, but clearly detectable, B220+ cells
(Table V
). Mice that received NOD.Kµnull bone
marrow plus B cells (lines 4 and 6) developed SAT comparable in
severity to the mice reconstituted with bone marrow from NOD.K
µ+ donors (lines 2 and 5), indicating that T
cells from B cell-deficient mice can induce SAT if B cells are
available when they are maturing from bone marrow precursors. Similar
results were obtained using either µ+ or
µnull mice as bone marrow recipients. Mice
reconstituted with NOD.Kµnull bone marrow plus
B cells produced IgG1 and IgG2b anti-MTg autoantibodies, and
autoantibody levels were comparable to those of mice reconstituted with
µ+ bone marrow. In contrast, unirradiated
NOD.Kµnull mice (line 7) and three of four
irradiated mice reconstituted with µnull bone
marrow (but no B cells; line 3) developed minimal or no SAT. With the
exception of one animal, mice in the latter group had virtually no
detectable splenic B cells, indicating that the majority of the mature
lymphocytes were derived from the bone marrow inoculum. The one animal
in line 3 that developed SAT was the only animal in this group that
produced clearly detectable anti-MTg autoantibody. Apparently some
B cells in this animal survived the irradiation, and although splenic B
cell numbers were low compared with the mice receiving the same bone
marrow cells with NOD.Kµ+ B cells (lines 4 and
6), there were apparently sufficient B cells for development of SAT and
production of autoantibody. There were insufficient
NOD.Kµnull mice available to transfer
µnull bone marrow to
µnull recipients.
| Discussion |
|---|
|
|
|---|
The fact that B cells had to be present during the first few-wk after birth or when T cells were developing from bone marrow precursors (Tables II-V) places some constraints on the potential mechanisms by which B cells could function in SAT. Previous studies have shown that CD4+ T cells from B cell-deficient mice can be activated by some foreign proteins or peptides (16, 17, 20, 24, 25, 26), but not others (17, 20, 24, 27, 28, 29, 30). The nature of the Ag, the activation state of the T cells, and the T cell function (e.g. proliferation, help to B cells) being assessed can all influence whether T cell activation occurs in B cell-deficient mice (16, 17, 20, 24, 26, 31). Dendritic cells are usually the most efficient APC for the initial sensitization of naive T cells, and B cells may function to amplify or sustain T cell responses initiated by other APC (9, 23, 32, 33, 35). In some previous studies, T cells from B cell-deficient mice could be activated when adult mice were reconstituted with B cells at the time of T cell priming (27, 28, 29, 30, 31), suggesting that B cells were necessary for initial T cell activation.
A role for B cells in activation of autoreactive T cells has been
demonstrated in some autoimmune disease models. For example,
autoreactive T cells were not activated spontaneously in SLE-prone B
cell-deficient mice (9, 10), and T cells from B
cell-deficient NOD mice could not be sensitized to the glutamate
decarboxylase (GAD) autoantigen (20, 34). Because B
cell-deficient mice also did not develop autoimmune disease, these
studies suggested B cells might function as APC for the activation or
diversification of autoreactive T cells (20, 23, 34, 35).
However, in a model of EAE induced by myelin oligodendrocyte
glycoprotein (MOG), B cell-deficient mice did not develop EAE, but
their T cells were apparently activated because they produced similar
amounts of Th1 cytokines upon restimulation by the major
encephalitogenic epitope (MOG 3555) as did T cells from similarly
immunized B cell-intact mice, which did develop EAE (16).
Another study showed that islet-reactive T cells were apparently
activated and could migrate to the pancreas in B cell-deficient NOD
mice, but the inflammatory response was mild, and diabetes did not
develop (8). These two studies suggested autoreactive T
cells could be activated in the absence of B cells, but the T cells
were not pathogenic. Falcone et al. (34) showed that T
cells from adult B cell-deficient NOD mice spontaneously proliferated
to GAD when B cells were added in vitro, suggesting that initial
sensitization to GAD did not require B cells, but B cells were required
as APC for amplification of the response. However, NOD B cells were
required for initial sensitization to GAD after immunization with GAD
in adjuvant (20). None of these studies have determined
when B cells were required for development of autoimmune disease. One
study showed that activated T cells could transfer diabetes to B
cell-deficient mice (36), suggesting B cells were not
required as APC for reactivation of T cells in the target organ or for
mediating damage to the pancreas. Consistent with the results reported
here (Table V
), T cells from B cell-deficient mice could induce
diabetes if they developed from bone marrow precursors in the presence
of B cells (20).
Our attempts to determine whether peripheral MTg-reactive T cells were
spontaneously activated in B cell-deficient mice were inconclusive,
possibly because MTg is a large protein with multiple potential T cell
epitopes, only some of which are pathogenic and/or may require B cells
for activation (37). If B cells function primarily as APC
for activation of pathogenic autoreactive T cells in SAT, it is
surprising the T cells were apparently not activated when B cells
became available in mice 68 wk of age (Tables II
and IV
). In the
experiment shown in Table IV
, B cells given to adult mice spontaneously
produced anti-MTg autoantibodies comparable to
NOD.Kµ+ mice, suggesting that failure to
spontaneously produce sufficient anti-MTg autoantibody does not
explain their inability to develop SAT. Although we cannot completely
exclude the possibility that B cell-deficient mice might have
eventually developed SAT in our experiments, a period of 1011 wk
after B cell reconstitution until assessment of SAT (Table II
) should
have been sufficient for T and B cells to migrate to the thyroid
(2, 3, 4, 5). In addition, one group of mice treated with
anti-IgM for 3 wk after birth was maintained on NaI water for 16 wk
instead of the usual 8 wk. These mice had autoantibody responses only
slightly lower than B cell-intact mice, but they developed minimal or
no SAT (Table II
, line 8). Although T cells from B cell-deficient NOD.K
mice could not be activated to induce SAT when B cells were made
available in adults, their T cells did induce SAT when they matured
from bone marrow precursors in the presence of B cells (Table V
). These
results indicate that T cells from B cell-deficient NOD.K mice can be
effectively activated to become effector cells for SAT if B cells are
present during their maturation.
The fact that mice reconstituted with B cells as adults do not develop SAT, while those given B cells during the maturation of T cells from bone marrow precursors do develop SAT, suggests the initial activation of autoreactive T cells may be an early event. If T cell activation does not occur before mice are about 6 wk of age, the T cells apparently are unable to respond even if B cells become available in adults. It is also possible, although probably less likely, that the T cell epitope that initiates SAT is only present in neonatal mice. Although tolerance to self Ags expressed in the thymus develops during ontogeny, T cells specific for self Ags not expressed in the thymus or expressed at levels that escape negative selection are present in the periphery at birth (38, 39, 40, 41, 42, 43, 44). These nontolerant, potentially autoreactive T cells can become activated in certain strains of mice, resulting in spontaneous autoimmune disease (44, 45); activation of such cells can be facilitated by B cells (9, 10, 23, 35, 46). Garza et al. (43, 44) showed that T cells able to respond to a physiologically expressed self Ag ZP3, expressed by the ovary are present in neonatal mice. Tolerance to ZP3 develops in the first week of life in female mice that express the Ag, but not in males that do not express ZP3 (44). Our results would be compatible with such a mechanism if B cells either produce or are required for presentation of the epitope that initiates SAT in NOD.H-2h4 mice. B cells that become available in adults may be unable to activate autoreactive T cells because the T cells able to respond to the epitope that initiates T cell activation in this model were eliminated or inactivated in the absence of B cells in neonates. Experiments to test this hypothesis are in progress.
Because thyroids of mice with SAT have many infiltrating B cells found
in clusters with CD4+ T cells,
(54), B cells could also be required
after T cells have migrated to the thyroid. Although B cells clearly
have an early role in SAT (Tables II-IV), B cells could also produce
autoantibodies or present Ag to T cells to amplify or sustain the
inflammatory response in the target organ. Ags presented to T cells in
the target organ could be proteins released during initial damage to
the thyroid or proteins that become iodinated when mice receive NaI in
their water. These Ags may differ from the Ag that initiates
autoreactive T cell activation, because B cells were initially required
well before cells migrated to the thyroid, and several weeks before
acceleration of SAT by NaI water (Tables II
and IV
). Studies are in
progress to determine whether B cells are required in the target organ
after autoreactive T cells have been activated. Although it seems
unlikely, the possibility that B cells that become available 68 wk
after birth differ from B cells of neonatal mice in their ability to
migrate to the thyroid cannot be ruled out. Some B cell-deficient mice
repopulated with B cells have mild thyroid lesions
(0+-1+). A few
B220+ cells are present in these thyroids,
whereas no B220+ cells were detected in the
0 ± 1+ lesions of B cell-deficient mice not
repopulated with B cells (S.Y., unpublished observations). These
results may suggest B cells given to adult mice are not inherently
unable to migrate to the thyroid, although this is difficult to prove,
as the numbers of infiltrating cells (T or B) in mice with such mild
lesions are very low.
To our knowledge, this is the first study to demonstrate an early role for B cells for development of a spontaneous autoimmune disease. A requirement for B cells or B cell Ig early after birth for activation of particular subsets of T cells has been demonstrated previously (17, 47, 48, 49, 50). B cells can also present Ig determinants to T cells (51), and natural IgM has been shown to play a role in maturation of the immune response (52). We have previously shown that normal mouse Ig could substitute for B cells in T cell activation (17). Normal mouse Ig given to anti-IgM treated or NOD.Kµnull mice using the regimen that was successful in our earlier study (17) had no effect on the ability of B cell-deficient mice to develop SAT (data not shown). This suggests that B cells probably do not simply provide Ig that could promote T cell activation or selection of the T cell repertoire by various mechanisms (47, 48, 49, 50, 51, 52), unless the Ig component is an autoantibody (53) and/or is unique to NOD.H-2h4 mice. To address some of these questions, we are generating NOD.Kµnull mice that express transgenic surface Ig+ B cells that do not secrete Ig (10) to provide a model in which B cells will be present at birth, but autoantibody will not be produced.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Helen Mullen, Division of Immunology, Department of Medicine, M450 Medical Sciences, University of Missouri School of Medicine, Columbia, MO 65212. ![]()
3 Abbreviations used in this paper: SAT, spontaneous autoimmune thyroiditis; MTg, mouse thyroglobulin; EAE, experimental allergic encephalomyelitis; GAD, glutamate decarboxylase; MOG, myelin oligodendrocyte glycoprotein. ![]()
Received for publication June 30, 2000. Accepted for publication September 18, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Yu, G. C. Sharp, and H. Braley-Mullen TGF-{beta} Promotes Thyroid Epithelial Cell Hyperplasia and Fibrosis in IFN-{gamma}-Deficient NOD.H-2h4 Mice J. Immunol., August 1, 2008; 181(3): 2238 - 2245. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yu, R. Dunn, M. R. Kehry, and H. Braley-Mullen B Cell Depletion Inhibits Spontaneous Autoimmune Thyroiditis in NOD.H-2h4 Mice J. Immunol., June 1, 2008; 180(11): 7706 - 7713. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. El Fassi, C. H Nielsen, H. C Hasselbalch, and L. Hegedus The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur. J. Endocrinol., May 1, 2006; 154(5): 623 - 632. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yu, P. K. Maiti, M. Dyson, R. Jain, and H. Braley-Mullen B cell-deficient NOD.H-2h4 mice have CD4+CD25+ T regulatory cells that inhibit the development of spontaneous autoimmune thyroiditis J. Exp. Med., February 21, 2006; 203(2): 349 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. McLachlan, Y. Nagayama, and B. Rapoport Insight into Graves' Hyperthyroidism from Animal Models Endocr. Rev., October 1, 2005; 26(6): 800 - 832. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Dunussi-Joannopoulos, G. E. Hancock, A. Kunz, M. Hegen, X. X. Zhou, B. J. Sheppard, J. Lamothe, E. Li, H.-L. Ma, P. R. Hamann, et al. B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model Blood, October 1, 2005; 106(7): 2235 - 2243. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Moore, H. Noorchashm, T. H. Lin, S. A. Greeley, and A. Naji NOD B-cells Are Insufficient to Incite T-Cell-Mediated Anti-islet Autoimmunity Diabetes, July 1, 2005; 54(7): 2019 - 2025. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. O'Neill, M. J. Shlomchik, T. T. Glant, Y. Cao, P. D. Doodes, and A. Finnegan Antigen-Specific B Cells Are Required as APCs and Autoantibody-Producing Cells for Induction of Severe Autoimmune Arthritis J. Immunol., March 15, 2005; 174(6): 3781 - 3788. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yu, G. C. Sharp, and H. Braley-Mullen Dual Roles for IFN-{gamma}, But Not for IL-4, in Spontaneous Autoimmune Thyroiditis in NOD.H-2h4 Mice J. Immunol., October 1, 2002; 169(7): 3999 - 4007. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Braley-Mullen, K. Chen, Y. Wei, and S. Yu Role of TGF{beta} in Development of Spontaneous Autoimmune Thyroiditis in NOD.H-2h4 Mice J. Immunol., December 15, 2001; 167(12): 7111 - 7118. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |